Modified 5-fluorouracil: Uridine phosphorylase inhibitor


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

5-Fluorouracil (5-FU) is a medication widely used in chemotherapy to treat various types of cancer. Being a substrate for the reverse reaction catalyzed by uridine phosphorylase (UPase), 5-FU serves as a promising prototype molecule (molecular scaffold) for the design of a selective UPase inhibitor that enhances the antitumor activity of 5-FU and exhibits intrinsic cytostatic effects on cancer cells. The chemical formula of the new compound, which binds to the uracil-binding site and, in the presence of a phosphate anion, to the phosphate-binding site of UPase, is proposed and investigated by molecular simulation methods.

About the authors

A. A. Lashkov

Shubnikov Institute of Crystallography of Federal Scientific Research Centre “Crystallography and Photonics”

Author for correspondence.
Email: alashkov83@gmail.com
Russian Federation, Leninskii pr. 59, Moscow, 119333

A. A. Shchekotikhin

Gause Institute of New Antibiotics

Email: alashkov83@gmail.com
Russian Federation, ul. Bol’shaya Pirogovskaya 11, Moscow, 119021

A. A. Shtil

Blokhin Russian Cancer Research Center

Email: alashkov83@gmail.com
Russian Federation, Kashirskoe sh. 23, Moscow, 115478

S. E. Sotnichenko

Shubnikov Institute of Crystallography of Federal Scientific Research Centre “Crystallography and Photonics”

Email: alashkov83@gmail.com
Russian Federation, Leninskii pr. 59, Moscow, 119333

A. M. Mikhailov

Shubnikov Institute of Crystallography of Federal Scientific Research Centre “Crystallography and Photonics”

Email: alashkov83@gmail.com
Russian Federation, Leninskii pr. 59, Moscow, 119333


Copyright (c) 2016 Pleiades Publishing, Inc.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies